SG11202008780SA - Biologically relevant orthogonal cytokine/receptor pairs - Google Patents

Biologically relevant orthogonal cytokine/receptor pairs

Info

Publication number
SG11202008780SA
SG11202008780SA SG11202008780SA SG11202008780SA SG11202008780SA SG 11202008780S A SG11202008780S A SG 11202008780SA SG 11202008780S A SG11202008780S A SG 11202008780SA SG 11202008780S A SG11202008780S A SG 11202008780SA SG 11202008780S A SG11202008780S A SG 11202008780SA
Authority
SG
Singapore
Prior art keywords
biologically relevant
receptor pairs
orthogonal cytokine
relevant orthogonal
cytokine
Prior art date
Application number
SG11202008780SA
Inventor
Kenan Christopher Garcia
Jonathan Sockolosky
Lora Picton
Original Assignee
Univ Leland Stanford Junior
Kenan Christopher Garcia
Jonathan Sockolosky
Lora Picton
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58240003&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11202008780S(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Leland Stanford Junior, Kenan Christopher Garcia, Jonathan Sockolosky, Lora Picton filed Critical Univ Leland Stanford Junior
Publication of SG11202008780SA publication Critical patent/SG11202008780SA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464416—Receptors for cytokines
    • A61K39/464419—Receptors for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
SG11202008780SA 2015-09-11 2019-03-08 Biologically relevant orthogonal cytokine/receptor pairs SG11202008780SA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562217364P 2015-09-11 2015-09-11
US201662375089P 2016-08-15 2016-08-15
US15/916,689 US10869887B2 (en) 2015-09-11 2018-03-09 Biologically relevant orthogonal cytokine/receptor pairs
PCT/US2019/021451 WO2019173773A1 (en) 2015-09-11 2019-03-08 Biologically relevant orthogonal cytokine/receptor pairs

Publications (1)

Publication Number Publication Date
SG11202008780SA true SG11202008780SA (en) 2020-10-29

Family

ID=58240003

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202008780SA SG11202008780SA (en) 2015-09-11 2019-03-08 Biologically relevant orthogonal cytokine/receptor pairs

Country Status (18)

Country Link
US (5) US10869887B2 (en)
EP (2) EP3347056A4 (en)
JP (5) JP7299021B2 (en)
KR (2) KR20180049080A (en)
CN (3) CN117659160A (en)
AR (1) AR114687A1 (en)
AU (3) AU2016318621A1 (en)
BR (1) BR112020018293A2 (en)
CA (2) CA2998393A1 (en)
HK (1) HK1258138A1 (en)
IL (1) IL277118A (en)
MX (1) MX2020009330A (en)
PH (1) PH12020551417A1 (en)
RU (1) RU2020133171A (en)
SG (1) SG11202008780SA (en)
TW (1) TW202017576A (en)
WO (2) WO2017044464A1 (en)
ZA (1) ZA202006168B (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180049080A (en) * 2015-09-11 2018-05-10 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 Biologically related orthogonal cytokine / receptor pairs
EP3596108A4 (en) 2017-03-15 2020-12-23 Pandion Operations, Inc. Targeted immunotolerance
MX2019013517A (en) 2017-05-24 2020-08-17 Pandion Operations Inc Targeted immunotolerance.
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
JP2022533702A (en) 2019-05-20 2022-07-25 パンディオン・オペレーションズ・インコーポレイテッド MAdCAM-targeted immune tolerance
US20220289807A1 (en) * 2019-08-13 2022-09-15 Amgen Inc. Interleukin-2 muteins for the expansion of t-regulatory cells
CA3150226A1 (en) * 2019-09-11 2021-03-18 Leon Lih-Ren SU Chimeric orthogonal receptor proteins and methods of use
IL293680B2 (en) * 2019-12-13 2024-04-01 Synthekine Inc Il-2 orthologs and methods of use
IL293978A (en) * 2019-12-20 2022-08-01 Regeneron Pharma Novel il2 agonists and methods of use thereof
CA3162406A1 (en) 2020-01-10 2021-07-15 Vijaya Raghavan PATTABIRAMAN Modified il-2 polypeptides and uses thereof
KR20220141299A (en) 2020-01-14 2022-10-19 신테카인, 인크. IL2 Orthologs and Instructions for Use
JP7303391B2 (en) 2020-01-14 2023-07-04 シンセカイン インコーポレイテッド Biased IL2 muteins, methods, and compositions
US20230027899A1 (en) * 2020-01-14 2023-01-26 Synthekine, Inc. Cd122 with altered icd stat signaling
EP4114441A4 (en) * 2020-03-05 2024-04-10 Univ Leland Stanford Junior Designed il-2 variants
EP4132543A2 (en) * 2020-04-06 2023-02-15 Synthekine, Inc. Human immune cells genomically modified to express orthogonal receptors
US20230159892A1 (en) * 2020-04-06 2023-05-25 Synthekine, Inc. Engineered immune cells
JP2023542049A (en) * 2020-09-01 2023-10-04 武田薬品工業株式会社 Interleukin-2 muteins and their uses
CN117377682A (en) * 2021-03-09 2024-01-09 宾夕法尼亚大学董事会 Selective stimulation of T cells in solid tumors using oncolytic virus delivery of orthogonal IL-2
EP4314050A1 (en) * 2021-04-02 2024-02-07 The Board of Trustees of the Leland Stanford Junior University Bispecific molecules and related compositions and methods
WO2023288283A2 (en) * 2021-07-14 2023-01-19 Synthekine, Inc. Methods and compositions for use in cell therapy of neoplastic disease
EP4293040A1 (en) 2022-06-19 2023-12-20 ETH Zurich Cell line for engineering cytokine receptors

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4902502A (en) * 1989-01-23 1990-02-20 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
EP1069917A4 (en) * 1998-03-20 2005-02-09 Genzyme Corp Novel complementing receptor-ligand pairs and adoptive immunotherapy using same
US6955807B1 (en) * 1998-05-15 2005-10-18 Bayer Pharmaceuticals Corporation IL-2 selective agonists and antagonists
AU2001266557A1 (en) * 2000-04-12 2001-10-23 Human Genome Sciences, Inc. Albumin fusion proteins
AU2002357784B2 (en) * 2001-12-04 2008-07-31 Merck Patent Gmbh Immunocytokines with modulated selectivity
US20060234205A1 (en) * 2004-03-05 2006-10-19 Chiron Corporation In vitro test system for predicting patient tolerability of therapeutic agents
US20060199250A1 (en) * 2005-03-04 2006-09-07 Huimin Zhao Method for generating a mutant protein which efficiently binds a target molecule
WO2008003473A2 (en) 2006-07-06 2008-01-10 Merck Patent Gmbh Compositions and methods for enhancing the efficacy of il-2 mediated immune responses
US8586532B2 (en) * 2007-08-24 2013-11-19 Novo Nordisk Healthcare A/G Method for selectively modifying a protein via transglutaminase catalyzed reaction
CA2795279C (en) * 2010-04-08 2020-05-05 Jn Biosciences Llc Antibodies to cd122
US10391126B2 (en) * 2011-11-18 2019-08-27 Board Of Regents, The University Of Texas System CAR+ T cells genetically modified to eliminate expression of T-cell receptor and/or HLA
WO2014184143A1 (en) * 2013-05-13 2014-11-20 Cellectis Cd19 specific chimeric antigen receptor and uses thereof
EP3824905A1 (en) * 2012-08-20 2021-05-26 Fred Hutchinson Cancer Research Center Method and compositions for cellular immunotherapy
US9434935B2 (en) * 2013-03-10 2016-09-06 Bellicum Pharmaceuticals, Inc. Modified caspase polypeptides and uses thereof
JP2016519651A (en) * 2013-03-15 2016-07-07 アンジェリカ セラピューティックス，インク． Modified toxin
CR20170510A (en) * 2015-04-10 2018-02-26 Amgen Inc INTERUQUINE MUTEINS 2 FOR THE EXPANSION OF REGULATORY T-CELLS
KR20180049080A (en) * 2015-09-11 2018-05-10 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 Biologically related orthogonal cytokine / receptor pairs
CN115073581A (en) * 2016-05-04 2022-09-20 美国安进公司 Interleukin-2 muteins for expansion of T regulatory cells

Also Published As

Publication number Publication date
MX2020009330A (en) 2021-02-26
JP2022025129A (en) 2022-02-09
EP3761997A1 (en) 2021-01-13
CA2998393A1 (en) 2017-03-16
CN117659160A (en) 2024-03-08
AR114687A1 (en) 2020-10-07
KR20210062591A (en) 2021-05-31
RU2020133171A (en) 2022-04-12
IL277118A (en) 2020-10-29
JP2024037778A (en) 2024-03-19
WO2019173773A1 (en) 2019-09-12
AU2019231997A1 (en) 2020-10-15
US10869887B2 (en) 2020-12-22
WO2017044464A1 (en) 2017-03-16
CA3093472A1 (en) 2019-09-12
TW202017576A (en) 2020-05-16
US20210060068A1 (en) 2021-03-04
AU2023203727A1 (en) 2023-07-06
EP3347056A4 (en) 2019-02-27
CN112272560A (en) 2021-01-26
JP2021516996A (en) 2021-07-15
ZA202006168B (en) 2022-01-26
KR20180049080A (en) 2018-05-10
EP3347056A1 (en) 2018-07-18
US11439664B2 (en) 2022-09-13
BR112020018293A2 (en) 2020-12-29
AU2016318621A1 (en) 2018-05-10
CN108430518A (en) 2018-08-21
HK1258138A1 (en) 2019-11-08
JP7299021B2 (en) 2023-06-27
US20190183933A1 (en) 2019-06-20
PH12020551417A1 (en) 2021-09-01
JP2018526020A (en) 2018-09-13
JP2024054175A (en) 2024-04-16
US20210069243A1 (en) 2021-03-11
US20180228842A1 (en) 2018-08-16
US20220354893A1 (en) 2022-11-10
EP3761997A4 (en) 2022-08-03

Similar Documents

Publication Publication Date Title
ZA202006168B (en) Biologically relevant orthogonal cytokine/receptor pairs
HK1252161A1 (en) Chimeric cytokine receptor
HK1252163A1 (en) Receptor
GB201621431D0 (en) Decoy cytokine receptor
GB2550801B (en) Adjustable bed
IL256655B (en) Support structure
GB2536629B (en) Adjustable scaffold
GB2544870B (en) Support apparatus
GB201522570D0 (en) Adjustable frameworks
SG11201709947XA (en) Adjustable mattress structure
SG11201800534YA (en) Grouting apparatus
GB2545475B (en) Adjustable food-portioning device
GB2543937B (en) Temporary Support
GB201721733D0 (en) Support apparatus
PT3078300T (en) Adjustable lounger
HUE052375T2 (en) Spreading apparatus
GB201505920D0 (en) Support apparatus
GB2552463B (en) Adjustable support
GB2544050B (en) Exercise mat
GB2538056B (en) Adjustable chair
GB201519130D0 (en) Support structure
GB201521764D0 (en) Support apparatus
GB201514147D0 (en) Support structure
GB201512346D0 (en) Adjustable post support
GB201505035D0 (en) Changing mat